{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:13:35Z","timestamp":1788779615998,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current widely used semiquantitative histological assessment methods are insensitive to identify subtle changes of liver fibrosis. Therefore, to precisely assess therapeutic efficacy on chronic hepatitis B (CHB), we explored the utility of qFibrosis (a fully-quantitative morphometric method employing second harmonic generation\/two photon excitation fluorescence) in liver fibrosis evaluation. Fibrosis changes were evaluated by Ishak fibrosis scoring and qFibrosis in CHB patients with paired liver biopsies before and after 78 weeks\u2019 antiviral therapy. A total of 162 patients with qualified paired biopsies were enrolled. Ishak fibrosis scoring revealed that 42.6% (69\/162) of the patients achieved fibrosis regression (\u22651-point decrease), 51.9% (84\/162) remained stable, and 5.5% (9\/162) showed progression (\u22651-point increase). qFibrosis showed similar trends in the groups of regression and progression patients as evaluated by Ishak. However, in Ishak stable patients, qFibrosis revealed hitherto undetected changes, allowing for further subcategorization into regression (<jats:italic>\u201cRegression by qFibrosis\u201d<\/jats:italic>; 40\/84, 47.6%), stable (29\/84, 34.5%), and progression (\u201c<jats:italic>Progression by qFibrosis<\/jats:italic>\u201d; 15\/84, 17.9%) groups. These newly fine-tuned categories were supported by changes of morphological parameters of fibrosis, collagen percentage area, and liver stiffness measurements. In conclusion, qFibrosis can be used to quantitatively identify subtle changes of liver fibrosis in CHB patients after antiviral therapy.<\/jats:p>","DOI":"10.1038\/s41598-018-21179-2","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T10:54:00Z","timestamp":1518087240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak \u201cstable\u201d patients on anti-HBV therapy"],"prefix":"10.1038","volume":"8","author":[{"given":"Yameng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-9861","authenticated-orcid":false,"given":"Yongpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lungen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiguo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemin","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tailing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil D.","family":"Theise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9409-1158","authenticated-orcid":false,"given":"Hong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"21179_CR1","doi-asserted-by":"crossref","unstructured":"Liaw, Y. F. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J Hepatol 59, 880\u2013881 (2013).","DOI":"10.1016\/j.jhep.2013.05.007"},{"issue":"Suppl 1","key":"21179_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/liv.12710","volume":"35","author":"P Bedossa","year":"2015","unstructured":"Bedossa, P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why? Liver Int 35(Suppl 1), 78\u201381 (2015).","journal-title":"Liver Int"},{"key":"21179_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468\u2013475 (2013).","journal-title":"Lancet"},{"key":"21179_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang, T. T. et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52, 886\u2013893 (2010).","journal-title":"Hepatology"},{"key":"21179_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","volume":"50","author":"P Bedossa","year":"2009","unstructured":"Bedossa, P. & Carrat, F. Liver biopsy: the best, not the gold standard. J Hepatol 50, 1\u20133 (2009).","journal-title":"J Hepatol"},{"key":"21179_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","volume":"13","author":"PJ Scheuer","year":"1991","unstructured":"Scheuer, P. J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13, 372\u2013374 (1991).","journal-title":"J Hepatol"},{"key":"21179_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24, 289\u2013293 (1996).","journal-title":"Hepatology"},{"key":"21179_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak, K. et al. Histological grading and staging of chronic hepatitis. J Hepatol 22, 696\u2013699 (1995).","journal-title":"J Hepatol"},{"key":"21179_CR9","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis, S. J. et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743\u20131751 (2006).","journal-title":"Gastroenterology"},{"key":"21179_CR10","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/hep.29009","volume":"65","author":"Y Sun","year":"2017","unstructured":"Sun, Y. et al. New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment. Hepatology 65, 1438\u20131450 (2017).","journal-title":"Hepatology"},{"key":"21179_CR11","doi-asserted-by":"publisher","first-page":"044013","DOI":"10.1117\/1.3183811","volume":"14","author":"DC Tai","year":"2009","unstructured":"Tai, D. C. et al. Fibro-C-Index: comprehensive, morphology-based quantification of liver fibrosis using second harmonic generation and two-photon microscopy. J Biomed Opt 14, 044013 (2009).","journal-title":"J Biomed Opt"},{"key":"21179_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2009.12.009","volume":"52","author":"L Gailhouste","year":"2010","unstructured":"Gailhouste, L. et al. Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis. J Hepatol 52, 398\u2013406 (2010).","journal-title":"J Hepatol"},{"key":"21179_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jhep.2014.02.015","volume":"61","author":"S Xu","year":"2014","unstructured":"Xu, S. et al. qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. J Hepatol 61, 260\u2013269 (2014).","journal-title":"J Hepatol"},{"key":"21179_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep12962","volume":"5","author":"TH Wang","year":"2015","unstructured":"Wang, T. H., Chen, T. C., Teng, X., Liang, K. H. & Yeh, C. T. Automated biphasic morphological assessment of hepatitis B-related liver fibrosis using second harmonic generation microscopy. Sci Rep 5, 12962 (2015).","journal-title":"Sci Rep"},{"key":"21179_CR15","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B. J Viral Hepat., https:\/\/doi.org\/10.1111\/jvh.12835 (2017).","DOI":"10.1111\/jvh.12835"},{"key":"21179_CR16","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/hep.22745","volume":"49","author":"V Calvaruso","year":"2009","unstructured":"Calvaruso, V. et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49, 1236\u20131244 (2009).","journal-title":"Hepatology"},{"key":"21179_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.21595","volume":"45","author":"ZD Goodman","year":"2007","unstructured":"Goodman, Z. D., Becker, R. L. Jr, Pockros, P. J. & Afdhal, N. H. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 45, 886\u2013894 (2007).","journal-title":"Hepatology"},{"key":"21179_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jhep.2014.03.006","volume":"61","author":"T Asselah","year":"2014","unstructured":"Asselah, T., Marcellin, P. & Bedossa, P. Improving performance of liver biopsy in fibrosis assessment. J Hepatol 61, 193\u2013195 (2014).","journal-title":"J Hepatol"},{"key":"21179_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jhep.2005.07.036","volume":"44","author":"S Nagula","year":"2006","unstructured":"Nagula, S., Jain, D., Groszmann, R. J. & Garcia-Tsao, G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 44, 111\u2013117 (2006).","journal-title":"J Hepatol"},{"key":"21179_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.1840200213","volume":"20","author":"M Chevallier","year":"1994","unstructured":"Chevallier, M., Guerret, S., Chossegros, P., Gerard, F. & Grimaud, J. A. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 20, 349\u2013355 (1994).","journal-title":"Hepatology"},{"key":"21179_CR21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.5858\/2000-124-1599-ROHC","volume":"124","author":"IR Wanless","year":"2000","unstructured":"Wanless, I. R., Nakashima, E. & Sherman, M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 124, 1599\u20131607 (2000).","journal-title":"Arch Pathol Lab Med"},{"key":"21179_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jhep.2015.11.012","volume":"64","author":"WR Kim","year":"2016","unstructured":"Kim, W. R. et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol 64, 773\u2013780 (2016).","journal-title":"J Hepatol"},{"key":"21179_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"European Association for Study of Liver","year":"2015","unstructured":"European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63, 237\u2013264 (2015).","journal-title":"J Hepatol"},{"key":"21179_CR24","doi-asserted-by":"crossref","unstructured":"Lefkowitch, J. H. Scheuer\u2019s Liver Biopsy Interpretation (9th ed). Edinburgh: Elsevier, 11\u201316 (2015).","DOI":"10.1016\/B978-0-7020-5548-5.00002-5"},{"key":"21179_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","volume":"48","author":"L Castera","year":"2008","unstructured":"Castera, L., Forns, X. & Alberti, A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48, 835\u2013847 (2008).","journal-title":"J Hepatol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21179-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21179-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21179-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:29:58Z","timestamp":1671589798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21179-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["21179"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-21179-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]},"assertion":[{"value":"13 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Theise consults for and received grants from Histoindex. Other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2989"}}